About Contact Us Careers
Sign In

Polycystic Kidney Disease Drugs Market Size & Share, by Type {Autosomal Dominant Polycystic Kidney Disease (ADPKD), Autosomal Recessive Polycystic Kidney Disease (ARPKD)}, by Treatment (Medication, Surgery); Diagnosis (Ultrasound, CT Scan, MRI Scan); End-user (Hospitals, Specialty Clinics) - Global Supply & Demand Analysis, Growth Forecasts, Statistics Report 2023-2033

  • Report ID: 4323
  • Published Date: Feb 22, 2023
  • Report Format: PDF, PPT

Companies Dominating the Polycystic Kidney Disease Drugs Landscape

top-features-companies
    • Otsuka Pharmaceutical Co., Ltd.
      • Company Overview
      • Business Strategy
      • Key Product Offerings
      • Financial Performance
      • Key Performance Indicators
      • Risk Analysis
      • Recent Development
      • Regional Presence
      • SWOT Analysis
    • Exelixis, Inc.
    • XORTX Therapeutics, Inc.
    • AstraZeneca PLC
    • Manros Therapeutics
    • Regulus Therapeutics Inc.
    • Reata Pharmaceuticals, Inc.
    • Pano Therapeutics, Inc.
    • Taro Pharmaceutical Industries Ltd.
    • GlaxoSmithKline plc.
Browse Key Market Insights with Data Illustration:

In the News

  • XORTX Therapeutics Inc. declared the positive outcomes from XRX-OXY-101 (“PK Clinical Trial”). The outcomes showed an increase in oral bioavailability for two versions compared to a control formulation in advance of ADPKD's late-stage phase 3 registration trial.

  • Pano Therapeutics, Inc. has acquired the privately-held NovaTarg Therapeutics, Inc. to strengthen Pano Therapeutic Inc’s drug discovery and development capabilities and enhance its portfolio.


Author Credits:  Radhika Gupta, Shivam Bhutani


  • Report ID: 4323
  • Published Date: Feb 22, 2023
  • Report Format: PDF, PPT

Frequently Asked Questions (FAQ)

The surge in the incidence of autosomal dominant polycystic kidney diseases (ADPKD), and growing initiatives to raise awareness about PKDs are the major factors driving the market growth.

The market is anticipated to attain a CAGR of 7% over the forecast period, i.e., 2023-2033.

Insufficient number of approved drugs, and strict government guidelines for drug trials are estimated to be the growth hindering factors for the market expansion.

The market in the North America region is projected to hold the largest market share by the end of 2033 and provide more business opportunities in the future.

The major players in the market are Otsuka Pharmaceutical Co., Ltd., Exelixis, Inc., XORTX Therapeutics, Inc., AstraZeneca PLC, Manros Therapeutics, Regulus Therapeutics Inc., Reata Pharmaceuticals, Inc., and others.

The company profiles are selected based on the revenues generated from the product segment, geographical presence of the company which determine the revenue-generating capacity as well as the new products being launched into the market by the company.

The market is segmented by type, treatment, diagnosis, end user, and by region.

The autosomal dominant polycystic kidney disease (ADPKD) segment is anticipated to garner the largest market size by the end of 2033 and display significant growth opportunities
Inquiry Before Buying Request Free Sample
  GET A FREE SAMPLE

FREE Sample Copy includes market overview, growth trends, statistical charts & tables, forecast estimates, and much more.

 Request Free Sample Copy

Have questions before ordering this report?

Inquiry Before Buying